Acute kidney injury associated with smoking synthetic cannabinoid

References

• Huffman JW, Padgett LW. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 2005; 12:1395–1411.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006; 30:S13–S18.
   PubMed Web of Science ®Google Scholar
• Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA. Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 2012; 1248:18–38.
   PubMed Web of Science ®Google Scholar
• U.S. DEA. 2011. National Forensic Laboratory DEA. Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2009–2010. Springfield, VA: U.S. Drug Enforcement Administration.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction 2009 Thematic paper — Understanding the ‘Spice’ phenomenon. Luxembourg: Office for Official Publications of the European Communities, 37 pp.
   Google Scholar
• Degenhardt L, Hall WD. The adverse effects of cannabinoids: implications for use of medical marijuana. CMAJ 2008; 178:1685–1686.
   PubMed Web of Science ®Google Scholar
• Castellanos D, Singh S, Thornton G, Avila M, Moreno A. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011; 49:347–349.
   PubMed Web of Science ®Google Scholar
• Meyer MR, Peters FT. Analytical toxicology of emerging drugs of abuse–an update. Ther Drug Monit 2012; 34:615–621.
   PubMed Web of Science ®Google Scholar
• Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013; 44:360–366.
   PubMed Web of Science ®Google Scholar
• Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011; 49:760–764.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108:534–544.
   PubMed Web of Science ®Google Scholar
• Alhadi S, Tiwari A, Vohra R, Gerona R, Acharya J, Bilello K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 2013; 9:199–206.
   PubMedGoogle Scholar
• Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012; 8:62–64.
   PubMedGoogle Scholar
• SAMSHA. 2011. Drug Abuse Warning Network (DAWN) 2010 ER Drug-related Visits.Substance Abuse and Mental Health Services Administration.
   Google Scholar
• American Association of Poison Control Centers. Synthetic Marijuana Data: March 31, 2013. Available from: http://www.aapcc.org/alerts/synthetic-marijuana/. Accessed 26 June 2013.
   Google Scholar
• National Conference of State Legislatures. Synthetic Cannabinoids (a.k.a. “K2”/”Spice”) Enactments. Available from: http://www.ncsl.org/issues-research/justice/synthetic-cannabinoids-enactments.aspx. Accessed 26 June 2013.
   Google Scholar
• Thornton SL, Lo J, Clark RF, Wu AH, Gerona RR. Simultaneous detection of multiple designer drugs in serum, urine, and CSF in a patient with prolonged psychosis. Clin Toxicol (Phila) 2012; 50: 1165–1168.
   PubMed Web of Science ®Google Scholar
• Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila) 2012; 50:733–742.
   PubMed Web of Science ®Google Scholar
• Gerona RR, Wu AH. Bath salts. Clin Lab Med 2012; 32:415–427.
   PubMed Web of Science ®Google Scholar
• Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 2012; 36:360–371.
   PubMed Web of Science ®Google Scholar
• Ammann J, McLaren JM, Gerostamoulos D, Beyer J. Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids. J Anal Toxicol 2012; 36:372–380.
   PubMed Web of Science ®Google Scholar
• Yanes EG, Lovett DP. High-throughput bioanalytical method for analysis of synthetic cannabinoid metabolites in urine using salting-out sample preparation and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 909:42–50.
   PubMed Web of Science ®Google Scholar
• Grabenauer M, Krol WL, Wiley JL, Thomas BF. Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. Anal Chem 2012; 84:5574–5581.
   PubMed Web of Science ®Google Scholar
• Di Paolo N, Guarnieri A, Loi F, Sacchi G, Mangiarotti AM, Di Paolo M. Acute renal failure from inhalation of mycotoxins. Nephron 1993; 64:621–625.
   PubMed Web of Science ®Google Scholar
• Warden CR, Benjamin DR. Acute renal failure associated with suspected Amanita smithiana mushroom ingestions: a case series. Acad Emerg Med 1998; 5:808–812.
   PubMed Web of Science ®Google Scholar
• Oubrahim H, Richard JM, Cantin-Esnault D. Peroxidase-mediated oxidation, a possible pathway for activation of the fungal nephrotoxin orellanine and related compounds. ESR and spin-trapping studies. Free Radic Res 1998; 28:497–505.
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 2004; 114:555–576.
   PubMed Web of Science ®Google Scholar
• Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011; 4:241–249.
   PubMedGoogle Scholar
• Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics 2012; 53:212–219.
   PubMed Web of Science ®Google Scholar
• Lewin AH, Seltzman HH, Carroll FI, Mascarella SW, Reddy PA. Emergence and properties of spice and bath salts: a medicinal chemistry perspective. Life Sci 2014; 97:9–19.
   PubMed Web of Science ®Google Scholar
• Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci 2014; 97:55–63.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use–multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93–98.
   PubMed Web of Science ®Google Scholar
• Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013; 8:523–526.
   PubMed Web of Science ®Google Scholar
• Thornton SL, Wood C, Friesen MW, Gerona RR. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila) 2013; 51:189–190.
   PubMed Web of Science ®Google Scholar
• Loeffler G, Hurst D, Penn A, Yung K. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces. Mil Med 2012; 177: 1041–1048.
   PubMed Web of Science ®Google Scholar
• Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: 2012 overview, key findings on adolescent drug use. University of Michigan, Institute for Social Research, 2013.
   Google Scholar
• U.S. Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012. pp 97–108.
   Google Scholar
• Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81:442–448.
   PubMed Web of Science ®Google Scholar
• Mammen C, Al Abbas A, Skippen P, Nadel H, Levine D, Collet JP, Matsell DG. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 2012; 59:523–530.
   PubMed Web of Science ®Google Scholar
• Lopes JA, Fernandes P, Jorge S, Goncalves S, Alvarez A, Costa e Silva Z, et al. Acute kidney injury in intensive care unit patients: a comparison between the RIFLE and the Acute Kidney Injury Network classifications. Crit Care 2008; 12:R110.
   PubMed Web of Science ®Google Scholar
• Langer N, Lindigkeit R, Schiebel HM, Ernst L, Beuerle T. Identification and quantification of synthetic cannabinoids in ‘spice-like’ herbal mixtures: a snapshot of the German situation in the autumn of 2012. Drug Test Anal. 2013.
   Google Scholar
• Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant 2006; 21: 2577–2582.
   PubMed Web of Science ®Google Scholar
• Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther 2013; 17:165–184.
   PubMed Web of Science ®Google Scholar
• Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, et al. Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem. 2013; 85:9390–9399.
   PubMed Web of Science ®Google Scholar
• Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 2012; 40:2174–2184.
   PubMed Web of Science ®Google Scholar
• Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 2011; 39:1967–1976.
   PubMed Web of Science ®Google Scholar
• Kneisel S, Teske J, Auwarter V. Analysis of synthetic cannabinoids in abstinence control: long drug detection windows in serum and implications for practitioners. Drug Test Anal 2014; 6:135–136.
   PubMed Web of Science ®Google Scholar
• Teske J, Weller JP, Fieguth A, Rothamel T, Schulz Y, Troger HD. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 2659–2663.
   PubMed Web of Science ®Google Scholar
• Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: mechanism underlying greater toxicity? Life Sci 2014; 97:45–54.
   PubMed Web of Science ®Google Scholar
• U.S. DEA, 2011. National Forensic Laboratory DEA. Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2009–2010. Springfield, VA: U.S. Drug Enforcement Administration.
   Google Scholar
• Sobolevsky T, Prasolov I, Rodchenkov G. Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 2012.
   Google Scholar
• Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008; 153:263–270.
   PubMed Web of Science ®Google Scholar
• Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50: 193–211.
   PubMed Web of Science ®Google Scholar
• Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011; 60:2386–2396.
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100:1538–1546.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Pan H, Rajesh M, Batkai S, Patel V, Harvey-White J, et al. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol 2010; 160:657–668.
   PubMed Web of Science ®Google Scholar
• Silva GB, Atchison DK, Juncos LI, Garcia NH. Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors. Am J Physiol Renal Physiol 2013; 304: F376–81.
   PubMed Web of Science ®Google Scholar
• Diffley M, Armenian P, Gerona R, Reinhartz O, Avasarala K. Catecholaminergic polymorphic ventricular tachycardia found in an adolescent after a methylenedioxymethamphetamine and marijuana-induced cardiac arrest. Crit Care Med 2012; 40:2223–2226.
   PubMed Web of Science ®Google Scholar
• Loeffler G, Penn A, Ledden B. “Bath salt”-induced agitated paranoia: a case series. J Stud Alcohol Drugs 2012; 73:706.
   PubMed Web of Science ®Google Scholar
• Shanks KG, Dahn T, Terrell AR. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 2012; 36:145–152.
   PubMed Web of Science ®Google Scholar
• Federal Register. Temporary scheduling of XLR-11. Published 2013 Apr 12.
   Google Scholar